The strategy to downregulate NOTCH1 activation by targeting its regulators could limit the detrimental effects caused by direct NOTCH1 inhibition and contribute to develop alternative therapeutic strategies not only for CLL but also for other NOTCH1-associated diseases. This evidence concerns the gene NOTCH1 and B-cell chronic lymphocytic leukemia.